CEBU, Philippines -- Structure Therapeutics, a clinical-stage biopharmaceutical company backed by venture capital investors, including Sequoia Capital China, has filed to raise $100 million in an initial public offering in the U.S.
The drugmaker, headquartered in California with research and development operations in China, is looking to list its American depositary shares (ADS) on Nasdaq under the symbol GPCR, according to its heavily redacted filing.
